Concord Medical Services Holdings Ltd CCM
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.10
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.0M | $51.3M | $73.3M | $65.3M | $69.5M | $26.1M | $20.1M | $27.8M | $50.9M | $65.5M |
| Cost of revenue | $62.2M | $63.4M | $86.5M | $90.5M | $85.1M | $32.2M | $30.8M | $24.9M | $35.8M | $41.3M |
| Gross profit | $3.7M | -$10.8M | -$10.8M | -$22.1M | -$8.9M | $2.0M | -$2.3M | $2.9M | $15.1M | $24.3M |
| SG&A | $30.5M | $55.4M | $46.5M | $45.1M | $54.6M | $45.2M | $45.3M | $42.4M | $36.5M | $29.7M |
| Operating income | -$37.4M | -$72.9M | -$65.2M | -$76.1M | -$71.9M | -$48.4M | -$62.8M | -$43.5M | -$32.6M | -$24.3M |
| Interest expense | $21.8M | $26.5M | $23.3M | $17.4M | $11.6M | $12.5M | $4.1M | $6.7M | $13.8M | $12.9M |
| Pre-tax income | -$53.4M | -$91.7M | $78.3M | $121.8M | $83.0M | $67.7M | $56.2M | $32.8M | -$39.0M | -$29.5M |
| Income tax | $867.0K | $2.4M | $3.5M | $10.3M | $1.0M | $5.8M | $5.6M | $5.0M | $4.9M | $8.7M |
| Net income | -$13.3M | -$42.2M | -$41.9M | -$71.0M | -$42.6M | -$47.5M | -$44.1M | -$34.2M | -$43.7M | -$37.7M |
| EPS, basic | -0.10 | -0.32 | -0.32 | -0.54 | — | — | — | — | — | -0.29 |
| EPS, diluted | -0.10 | -0.32 | -0.32 | -0.54 | -0.98 | -0.78 | -0.61 | -0.40 | -0.34 | -0.29 |
| Shares, diluted (wtd. avg.) | $131.1M | $131.1M | $131.1M | $131.1M | $131.1M | $131.1M | — | — | — | $130.6M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $42.6M | $33.9M | $12.4M | $22.4M | $23.0M | $70.0M | $11.4M | $118.8M | $96.3M | — |
| Short-term investments | — | $18.4M | — | — | — | — | $0 | $7.3M | — | — |
| Receivables | $6.3M | $7.0M | $10.4M | $18.9M | $20.1M | $11.9M | $10.6M | $12.6M | $20.3M | $27.3M |
| Inventory | $6.6M | $4.6M | $5.7M | $12.3M | $6.0M | $3.3M | $624.0K | $488.0K | $966.0K | $853.0K |
| Total current assets | $134.7M | $134.8M | $86.9M | $110.2M | $91.7M | $103.6M | $40.6M | $178.7M | $170.8M | $172.1M |
| Property, plant and equipment | $532.6M | $507.5M | $499.6M | $472.5M | $493.5M | $392.2M | $272.8M | $177.3M | $122.0M | $111.7M |
| Goodwill | $81.8M | $81.8M | $78.8M | $81.0M | $84.4M | $57.8M | $32.3M | $23.7M | $0 | — |
| Other intangibles | $36.6M | $40.0M | $45.5M | $51.3M | $103.2M | $80.1M | $76.5M | $66.4M | $1.2M | $2.5M |
| Total assets | $936.3M | $921.5M | $852.7M | $870.6M | $977.6M | $817.6M | $617.3M | $666.9M | $532.6M | $465.0M |
| Accounts payable | $17.1M | $27.3M | $18.2M | $21.3M | $16.1M | $2.9M | $1.2M | $791.0K | $701.0K | $295.0K |
| Short-term debt | $78.7M | $52.5M | $101.8M | $49.9M | $25.6M | $19.1M | $6.2M | $6.4M | $30.3M | $11.9M |
| Total current liabilities | $279.5M | $291.2M | $274.8M | $162.6M | $126.2M | $78.5M | $90.1M | $126.6M | $170.3M | $137.0M |
| Long-term debt | $352.6M | $369.0M | $280.9M | $358.3M | $341.9M | $301.6M | $185.6M | $72.4M | $43.7M | $31.1M |
| Total liabilities | $671.7M | $699.9M | $606.6M | $578.4M | $547.1M | $449.6M | $345.9M | $336.2M | $376.6M | $287.6M |
| Retained earnings | -$638.6M | -$599.1M | -$572.5M | -$546.2M | -$514.3M | -$376.5M | -$256.5M | -$179.3M | -$135.2M | -$86.2M |
| Total equity | -$300.7M | -$312.4M | -$298.9M | -$270.3M | -$215.0M | -$101.6M | -$17.6M | $63.6M | $143.6M | $168.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$28.9M | -$54.5M | -$38.9M | -$31.4M | -$56.4M | -$35.2M | -$28.1M | -$5.6M | $4.1M | -$11.2M |
| Depreciation and amortisation | $14.8M | $11.6M | $11.6M | $12.9M | $10.1M | $8.4M | $6.4M | $5.9M | $12.8M | $16.9M |
| Stock-based compensation | — | — | — | -$858.0K | $2.3M | $3.2M | $3.0M | $1.6M | $1.8M | $1.2M |
| Capital expenditure | $8.1M | $20.7M | $15.9M | $32.3M | $43.8M | $25.8M | $33.4M | $24.1M | $14.0M | $11.4M |
| Investing cash flow | $7.7M | -$81.3M | -$6.7M | -$17.2M | -$88.8M | -$81.8M | -$153.9M | -$145.5M | -$48.1M | -$10.8M |
| Financing cash flow | $28.2M | $157.0M | $36.3M | $55.5M | $100.8M | $174.5M | $73.7M | $175.0M | $29.9M | -$18.9M |
| Dividends paid | — | — | — | — | — | — | — | $0 | $0 | $41.2M |
| Buybacks | — | — | — | — | — | — | — | $0 | $0 | $4.4M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-050692.
Others in SIC 8011
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| HIMS | Hims & Hers Health, Inc. | $6.42B | 54.3x | 59.0% |
| TDOC | Teladoc Health, Inc. | $1.14B | — | -1.5% |
| STLN | Starling Oncology, Inc. | $604.4M | — | 27.8% |
| SBC | SBC Medical Group Holdings Inc | $423.7M | 8.2x | -15.5% |
| AIRS | Airsculpt Technologies, Inc. | $201.5M | — | -15.8% |
| LFMD | LifeMD, Inc. | $148.5M | 12.3x | 25.3% |
| BMGL | Basel Medical Group Ltd | — | — | — |